This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.
Women using a combined oral contraceptive (COC) and who have decided to stop it or switch it to a non-estrogenic contraceptive are included. At baseline, before the COC is stopped, and at multiple time points during the 3 months of follow-up, blood will be drawn to evaluate the hemostatic profile. Findings are compared with a control group of women without an estrogenic contraceptive, who are also followed for 3 months.
Study Type
OBSERVATIONAL
Enrollment
103
Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
Geneva University Hospitals
Geneva, Switzerland
Change in normalized APC sensitivity ratio
Time frame: Three months
Change in Endogenous Thrombin Potential (Thrombin Generation Assay)
Time frame: Three months
Change in concentrations of sex hormone-binding globulin
Time frame: Three months
Change in fibrinolysis assay
Time frame: Three months
Change in individual coagulation factors
The following coagulation factors will be assessed: fibrinogen, protein C, protein S, antithrombin, factor VIII
Time frame: Three months
Contraception-related satisfaction
Satisfaction will be estimated by the use of the Ortho Birth Control Satisfaction Assessment Tool questionnaire.
Time frame: Three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.